Presented by cshlpress…

• The big non-ASCO story of the day was AstraZeneca and Merck. The two pharma giants announced a collaboration to research a novel combination anticancer regimen composed of two investigational compounds, MK-2206 from Merck and AZD6244 (ARRY-886) from AstraZeneca. [Pharmalive]

• Novartis’ Reclast (zoledronic acid) won approval by the FDA as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. [PRNewswire]

• Pfizer halts study of advanced breast cancer treatment with Sutent. [The Day]

• Bayer getting sued over Yaz deaths, blood clots!! [BNET Pharma]

• Bausch & Lomb settles 600 eye fungus lawsuits for $250M – so far. [Yahoo!Finance]

• TorreyPines officially enters the Graveyard. [BioSpace]

• A government study finds that Forest Laboratories’ Celexa, widely prescribed for autistic children, doesn’t help reduce their repetitive behaviors and even caused some of them to have nightmares. [Bloomberg]

• Finally, can the world stand a world where actress Brooke Shields has brown eyes instead of blue ones?? Damn you, Latisse!!! [PharmaMarketing]

ASCO Final Roundup Part 2

• Plexxikon’s BRAF inhibitor, PLX4032, shows positive results in melanoma study. [The Guardian]

• Xencor presented results from its Phase I study of XmAb®2513 in patients with relapsed Hodgkin lymphoma (HL). [Genetic Engineering & Biotechnology News]

• Exelixis (EXEL) presented data from an ongoing Phase 1 dose-escalation trial of XL147, an oral phosphoinositide-3-kinase (PI3K) inhibitor, in patients with solid tumors. [Yahoo!Finance]

• OXiGENE (OXGN) reported positive data from its investigator-sponsored Phase 2 trial of ZYBRESTAT in patients with platinum-resistant ovarian cancer. [GlobeNewswire]

• Finally, More ASCO from the Journal! [WSJ Health Blog]

Anonymous Tip? Comments? Contact us at: hr@iguanabio.com

Related Posts